Search hospitals > Michigan > Muskegon

Cancer and Hematology Centers of Western Michigan - Norton Shores

Claim this profile
Muskegon, Michigan 49444
Global Leader in Skin Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
120 reported clinical trials
1 medical researcher
Photo of Cancer and Hematology Centers of Western Michigan - Norton Shores in Muskegon

Summary

Cancer and Hematology Centers of Western Michigan - Norton Shores is a medical facility located in Muskegon, Michigan. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Cancer and Hematology Centers of Western Michigan - Norton Shores is involved with conducting 120 clinical trials across 279 conditions. There are 1 research doctors associated with this hospital, such as Kathleen J. Yost.

Area of expertise

1Skin Cancer
Global Leader
Cancer and Hematology Centers of Western Michigan - Norton Shores has run 57 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
Cancer and Hematology Centers of Western Michigan - Norton Shores has run 21 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Cancer and Hematology Centers of Western Michigan - Norton Shores

Breast Cancer
Skin Cancer
Lung Cancer
Bladder Cancer
Breast cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
Cutaneous Melanoma
Cancer
Multiple Myeloma
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Low Dose Tamoxifen

for Breast Cancer

This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Cancer and Hematology Centers of Western Michigan - Norton Shores?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security